Across TCGA pan-cancer cohorts, GAPDHP25 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated GAPDHP25 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GAPDHP25 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GAPDHP25 expression acts as an unfavorable survival marker, although some lineages such as UVM and READ show a favorable association.
LIHC, LGG, and BLCA are the cancer types where GAPDHP25 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.